British biopharmaceutical giant AstraZeneca plans to invest $50 billion in the United States by 2030, expanding its presence ...

We recently published 8 Stocks That Jim Cramer Recently Talked About. Bristol-Myers Squibb Company (NYSE:BMY) is one of the ...

This was the stock's second consecutive day of losses.

Despite not meeting the endpoint, subjects have experienced a meaningful improvement in RBC transfusion independence.

Bristol Myers Squibb said the U.S. Food and Drug Administration has accepted its application seeking expanded approval of its plaque psoriasis drug Sotyktu for the treatment of adults with active ...

The US Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) for Sotyktu ...

The Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) for deucravacitinib for the treatment of adults with active psoriatic arthritis (PsA).

In July 2025, Inovio Pharmaceuticals conducted a Phase 1/2 trial to evaluate safety, immunogenicity and preliminary efficacy ...

A new genetic test, based on data from more than five million people, can identify people at risk of severe obesity. The test can be performed on children before their genetic risk starts to shape ...

Biogen will invest an extra $2 billion to expand its RTP facilities, focusing on AI-driven manufacturing and late-stage ...

Icotrokinra is a first-in-class targeted oral peptide that blocks interleukin (IL) 23 and its receptor, which plays a key role in the inflammatory response in plaque psoriasis.

The Nuclear and Radiation Safety Bill 2024 is a legal framework for the safe use of nuclear technology and radiation sources.